Lupus

This study evaluated the risk of flares after sustained drug-free rem in SLE. % of pts w/ reported flares w/n yrs in rem: 48.6% at 2yrs 42.3% at 3yrs 35.2% at 5 yrs Mucocut, msk, renal & immuno - ⬆️affected domain Reassess pts regularly. POS1354 @RheumNow #EULAR2026 https://t.co/DG0yNOW1nh

Links:

sheila @RHEUMarampa( View Tweet )
@RheumNow article further exploring the roe of lung ultrasound for RA-ILD screening as shown through 3 #EULAR2026 abstracts https://t.co/smN8hg51nj

Links:

Jiha Lee @JihaRheum( View Tweet )

What’s new with the 2026 update of reco for vax in AIIRD? Vaccinate as soon as possible Non-live vaccines are safe Hold MTX for upto 2wks to inc vax yield Strong reco for RZV Catch-up vax for HPV in SLE Rotavirus vax for newborns exposed in utero to TNFi @RheumNow #EULAR2026 https://t.co/RZbyvAcYRI

Links:

sheila @RHEUMarampa( View Tweet )
Good performance of #definite #antisynthetase #syndrome ✅+antibody mandatory Possible also does ok @RheumNow #EULAR2026 June 6 #antisynthetase #classifiaction #criteria https://t.co/5sxogTX9YT

Links:

Janet Pope @Janetbirdope( View Tweet )
Dr. Cavagna presents the 2025 EULAR/ACR Classification Criteria for Anti-Synthetase Syndrome He emphasizes the inportance of ruling out anti-MDA5 Ab & anti-PM/Scl Ab DM since these conditions share overlapping features w/ ASyS. @RheumNow #EULAR2026 https://t.co/AtGRlp5qyW

Links:

sheila @RHEUMarampa( View Tweet )
Do u screen your SLE pts for OP? In this real-world multicenter study, SLE pts who were likely to be tested for BMD were older, had MSK s/sxs, sSJg & longer GC exposure. RFs for OP: LN, higher dse. activity, longer GC use, high cumulative GC dose POS1372 @RheumNow #EULAR2026 https://t.co/pAxhOPGGYs

Links:

sheila @RHEUMarampa( View Tweet )
#EULAR2026 POS1139 Pay attention in #SLE with anti-Sm+ RNP+. Data from 3 RCTs & a cohort: -enriched in Black patients -poor response to B-cell depletion inc. Obi -non-response is assoc. with BAFF-dependent B-cell repopulation. So, use Belimumab -High ferritin = flare @RheumNow https://t.co/3uDMigY8i2

Links:

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
lupus.nephritis.immunofluorescence.jpg

Obinutuzumab drives histologic remission in lupus nephritis

Mrinalini Dey, MD

At EULAR 2026, investigators are presenting perhaps the most biologically compelling data yet from the REGENCY trial, with evidence that obinutuzumab induces deep intrarenal B-cell depletion alongside markedly higher rates of histological remission.

Read Article
Abstr LB0003 Off-the-shelf allogeneic NK cell therapy + rituximab in refractory RA, Sjögren disease, and systemic sclerosis. 31 patients. Outpatient administered. RA at 6 months: 71% ACR50, mean CDAI change −36.8. SSc: 100% rCRISS25 response. SjD: 86% ClinESSDAI responders. https://t.co/60046jgYia

Links:

Antoni Chan MD (Prof) @synovialjoints( View Tweet )
Interesting data on the effect of AB-101 + RTX on refractory RA, SSc and SjD. Curious about long term results and potential position in tx strategies LB0006 @RheumNow #EULAR2026 https://t.co/opbh8yGmwO

Links:

sheila @RHEUMarampa( View Tweet )
#SLE Rx options Determining #MOA #TYK2 #sig w #deucravacitinib #IFN sig in active #SLE ⬇️ in #anifrolumab #upa #deucra #repeat renal #bx in #obinutuzimab ➡️ Clears B cells #Dapriluzimab & other MOAs ⬇️AntiDNA ⬆️complements #EULARbest @RheumNow #EULAR2026 #POS1364, OP0160,336

Janet Pope @Janetbirdope( View Tweet )

#EULAR2026 LB0003 CAR-T is not scalable. In a Phase 2a of off-the-shelf AB-101 allogenic NK + low dose conditioning (Cyclo & Flud) + Rituximab: preliminary efficacy & safety profile in severe-refractory RA (N=15), SjD (11), SSc (5). Longer FU & Comparator is needed @RheumNow https://t.co/gQniufREQC

Links:

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
#EULAR2026 LB0004 First BiTE, now TriTE! Tri-specific CC312 CD19/CD3/CD28 (i.e. CD28 co-stimulates Tcell activation) showed deep Bcell depletion, early efficacy & safety in 10 #SLE patients up to 52WKs. Promising but longer FU needed to see if repeat dosing needed @RheumNow https://t.co/6Lbm9LYJrY

Links:

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
JASMINE-SLE: Proof of concept study on Nipocalimab for SLE SRI-4 met at wk 24 for the 15 mg/kg q2w dose va. PBO Improvement of SRI-4 composite & LLDAS at wk 52 LB0007 @RheumNow #EULAR2026 https://t.co/0wzHyid3dy

Links:

sheila @RHEUMarampa( View Tweet )
#EULAR2026 LB0006 Beyond conventional immunosuppressant, a multicentre RCT (N=145) in China showed mTOR-i Sirolimus + SOC met primary endpoint (SRI-4) vs PBO + SOC in #SLE. Favourable safety. Frequent AE: high cholesterol & low WCC. Unclear position in treatment pathway @RheumNow https://t.co/OiFp06467v

Links:

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
5 top abstracts in #Myositis @eular_org 1 #Nailfold #capillaries as an early marker of #IIM Rx 2 #brepocitinib +RCT #DM 3 & rapid skin improvement #CLASI 4 #Ab may help #IBM but neg primary endpoint 5 #criteria for #antisynthetase #EULAR2026 @RheumNow OP0168, 0166, 0164 POS264

Janet Pope @Janetbirdope( View Tweet )

Top 5 abst in #SjD #anifrolumab +RCT #ianalumab LTE Rx sustained #telitatacept +LTE #iana improves u/s parotids #TYK2 sig in#SjD OP0002, 0126, 127, 160 POS0284 #EULARbest #EULAR2026 @RheumNow @eular_org

Janet Pope @Janetbirdope( View Tweet )

#EULAR2026 LB0007 Phase 2 RCT of Nipocalimab, an FcRn-i in moderate-to-severe #SLE, with mandatory GC taper =<7.5mg/d by WK16: met primary endpoint at WK24 (SRI-4) vs PBO. Effect size better in Ab+, Ab-High & IFN-High. 23% had IgG<3 at WK58 but SIE. Phase 3 is underway @RheumNow https://t.co/EpgNOHcEqC

Links:

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Do you target #DORIS / remission in #SLE pts #EULAR2026 @RheumNow @eular_org

Janet Pope @Janetbirdope( View Tweet )

Aiming for #DORIS #SLE #remission Or #LLDAS in #SLE Related to ⬆️survival #deep outcome in RCTs ➡️archived in #deucravacitinib ph2 #LTE & ph3 #dapirolizumab & #obintuzimab -achieved in #CAR-T trials in #lupus POS0683, 1364, 0695, OP0338 & several 🚗 T abst #EULAR2026 @RheumNow

Janet Pope @Janetbirdope( View Tweet )

Data of #Rituximab In #SARD-ILD Small N of #RA-#ILD pts I think data are sufficient as #RWE of #RTX in RA-ILD ✅benefits in other #CTD ILD ✅benefits in #rheumatoid #arthritis #EVER-ILD #RCT HOT #RA-ILD topic June 5 #EULAR2026 @RheumNow https://t.co/61MbsnNsaf

Links:

Janet Pope @Janetbirdope( View Tweet )
Is there enough data to recommend #rituximab For #ILD in #rheumatoid #arthritis @RheumNow #EULAR2026

Janet Pope @Janetbirdope( View Tweet )

TRM-SLE is a novel clinical outcome assessmentfor use in #SLE trials 8 domains: mucocutaneous, arthritis, hemolytic anemia, thrombocytopenia, nephropathy, serositis Developed via multistage consensus process Higher pt enrollment potential? POS1068 @RheumNow #EULAR2026 https://t.co/W614xZV7TX

Links:

sheila @RHEUMarampa( View Tweet )
#EULAR2026 There are over 90 abstracts on CAR-T. Please read my article on a selection of abstracts pertaining to the progress of CAR-T in rheumatic and musculoskeletal diseases @RheumNow https://t.co/2Uxy3uyF6H https://t.co/VulhEDJTEi

Links:

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
One of the highlights of #EULAR2026 for me: ♀️The "This Is a Woman's World" session I recapped 8 must-know abstracts (including our work from ARCH_ArLAR) in a new @RheumNow video🎬 https://t.co/3jwJIegGg4 via @YouTube @ArLARheumatolog https://t.co/Azvkl2sjdu

Links:

Nelly ZIADE 🍀 @Nellziade( View Tweet )

Therapeutic Updates

Expert insights on the 2024 ACR Guideline recommendations for lupus nephritis

Sponsored by Aurinia
Aurinia 2026 May RX Update
Two experts in lupus care offer a balanced perspective on applying the updated ACR Guideline recommendations and the clinical nuances of managing lupus nephritis.
Read Post

Recent Blogs

Advanced Practice Rheum

Systemic Lupus Erythematosus

Jack Cush, MD
APR SLE VIDEO COVER
Dr. Cush reviews systemic lupus erythematosus.
Read Article
Advanced Practice Rheum

Evaluation of Rheumatic Complaints

Jack Cush, MD
Eval of Rheum Complaints Cover Image
Dr. Cush provides a systematic approach to evaluating musculoskeletal and rheumatic complaints in clinical practice.
Read Article
rheumthought

CNS Lupus (NPSLE)

Jack Cush, MD
Cush RhTh CNS
29 yr. old woman with SLE and transverse myelitis. Is this NPSLE; how to diagnose?
Read Article
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

Podcasts

  • EULAR 2026 Daily Podcast Day 2c
  • EULAR 2026 Daily Podcast Day 1a
  • ACR 2025 Daily Podcasts Day4a
×